For instance, using MLN8237 to target inhibition of amplification and up-regulation of proto-oncogenes such as N-MYC and Aurora kinase A (AURKA) can partially impede the progression of PCa and CRPC to NEPC [13,40]. The gene discussed is MYCN; the disease is posterior cortical atrophy.